Gene therapy success for anaemia patient

September 15, 2010

In a rare success for the much-headlined vision of gene therapy, scientists said on Wednesday they had corrected flawed DNA in an 18-year-old man suffering from a debilitating form of anaemia.

The unnamed patient received a gene that corrected a blood disorder known as beta-thalassaemia and three years on, his health is "remarkable" and his quality of life good, they said.

Beta-thalassaemia occurs when a patient is unable to produce enough beta-globin, a component in haemoglobin, which is used by red blood cells to transport oxygen around the body.

The body's organs, depriving of sufficient oxygen, can be badly damaged without regular, and lifelong, blood transfusions.

The alternative treatment is bone marrow transplant, but only a small minority of patients have access to this because of difficulties in finding the right type of donor.

Reporting in the science journal Nature, doctors led by Philippe Leboulch of Harvard Medical School, used a virus as a "Trojan horse" to deliver a slice of DNA into cells which corrected for the flawed beta-LCR gene.

"At present, approximately three years post-transplantation, the biological and clinical evolution is remarkable and the patient's quality of life is good," they said.

The patient, who had been received blood transfusions since the age of three, last received donated blood in June 2008, a year after the operation.

Leboulch sounded a note of caution, saying that the Trojan horse, a type of virus that is called a lentivirus, may have altered the function of a gene that controls the behaviour of blood stem cells.

As a result, there has been a mild expansion in the number of these cells.

At present, the increase is benign, but in theory it could be a prelude to leukaemia, which is a factor for doctors weighing whether to use the therapy on other patients.

Gene therapy burst on the medical scene in the late 1990s, offering the allure of blocking or reversing inherited disease.

So far, though, successes have been few, limited to single-gene disorders -- as opposed to complex multi-gene disorders that account for the commonest diseases -- and they have been carried out under tightly-controlled lab conditions.

They include six children, blighted by a retinal disease called Leber's congenital amaurosis and two adults with a so-called myeloid disorder, a disease of white blood cells.

But there have also been setbacks, including the tragic death of an 18-year-old US volunteer, Jesse Gelsinger, in 1999, and the development of cancer among two French children treated for "bubble baby" syndrome, a chronic lack of immune defences.

Investigations into these failures have focussed especially on the virus used to deliver the gene, amid suspicions that the vector -- even if disabled -- may unleash an uncontrolled response from the immune system.

Related Stories

Beta-thalassemia is a serious, potentially life-threatening disease that affects red blood cells, cells that carry oxygen via hemoglobin throughout the body. As part of the SardiNIA Study of Aging, supported by the National ...

Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hospital have alleviated sickle cell disease pathology. In their studies, the researchers found that the ...

A strategy that combines gene therapy with blood stem cell therapy may be a useful tool for treating a fatal brain disease, French researchers have found. These findings appear in the 6 November 2009 issue of the journal ...

Researchers have developed an experimental cure for Type 1 diabetes, a disease that affects about one in every 400 to 600 children and adolescents. They will present their results in a mouse model of Type 1 diabetes on Sunday ...

Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (ß-globin) in patients' ...

Recommended for you

A biomedical breakthrough published today in the journal Nature reveals never-before-seen details of the human body's cellular switchboard that regulates sensory and hormonal responses. The work is based on an X-ray laser ...

(PhysOrg.com) -- The ability to remember the past and imagine the future can significantly affect a person's decisions in life. Scientists refer to the brains ability to think about the past, present, and future as ...

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

(PhysOrg.com) -- Most people can easily tell the difference between reality and fantasy. We know that characters in novels and movies are fictitious, and we also understand that historical figures - even if we’ve never ...

(PhysOrg.com) -- Humans don’t always make the most rational decisions. As studies have shown, even when logic and reasoning point in one direction, sometimes we chose the opposite route, motivated by personal bias or simply ...

1 comment

"Gene therapy burst on the medical scene in the late 1990s, offering the allure of blocking or reversing inherited disease.

So far, though, successes have been few, limited to single-gene disorders -- as opposed to complex multi-gene disorders that account for the commonest diseases -- and they have been carried out under tightly-controlled lab conditions."

Err no, this is a classic example of researchers out of touch with the rest of the scientific world.Marshall Protocol, developed in Australia and the States is gene therapy and there are thousands of us around the world.Drugs are available now with authorities in place in some countries for medicare rebates.